Online citations, reference lists, and bibliographies.

Inhibition Of Vascular Endothelial Growth Factor Prevents Retinal Ischemia-associated Iris Neovascularization In A Nonhuman Primate.

Anthony P. Adamis, David T. Shima, Michael J. Tolentino, Evangelos S. Gragoudas, Napoleone Ferrara, Judah Folkman, Patricia A D'Amore, Joan W Miller
Published 1996 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
OBJECTIVE To determine if the angiogenic peptide vascular endothelial growth factor (VEGF) is required for retinal ischemia-associated iris neovascularization in a nonhuman primate. METHODS Laser retinal vein occlusion was used to produce retinal ischemia in 16 eyes of eight animals (Macaca fascicularis). Eyes were randomized to treatment every other day with intravitreal injections of either a neutralizing anti-VEGF monoclonal antibody or a control monoclonal antibody of the same isotype. Serial iris fluorescein angiograms were assessed using a standardized grading system and masked readers. Retinal VEGF and placental growth factor expression were assessed by Northern blotting. The specificity of the antibodies was determined in capillary endothelial cell proliferation assays prior to intravitreal injection. RESULTS Zero of eight eyes receiving the neutralizing anti-VEGF antibodies developed iris neovascularization. Five of eight control antibody-treated eyes developed iris neovascularization. The difference was statistically significant (P = .03). Intravitreal antibody injection did not impair the ability of the ischemic retina to increase VEGF messenger RNA expression. The anti-VEGF antibodies specifically inhibited VEGF-driven capillary endothelial cell proliferation in vitro. CONCLUSION These data demonstrate that VEGF is required for iris neovascularization in an adult nonhuman primate eye. The inhibition of VEGF is a new potential therapeutic strategy for the treatment of ocular neovascularization.

This paper is referenced by
A model system for the study of human retinal angiogenesis: activation of monocytes and endothelial cells and the association with the expression of the monocarboxylate transporter type 1 (MCT-1)
Rachel M. Knott (1999)
VEGF-induced corneal neovascularisation in a rabbit experimental model.
Laurențiu Coman (2010)
Ligands of peroxisome proliferator-activated receptor-gamma increase the generation of vascular endothelial growth factor in vascular smooth muscle cells and in macrophages.
Alicja Józkowicz (2000)
The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas
T. Murata (1997)
Ophthalmic Application of Anti-VEGF Therapy.
Timothy Y Y Lai (2017)
Insulin-like growth factor binding protein-3 in preterm infants with retinopathy of prematurity
Manizheh Mostafa Gharehbaghi (2012)
Growth Factors in Proliferative Diabetic Retinopathy
Zia Ali Khan (2003)
Utilisation des anti-VEGF dans la dégénérescence maculaire liée à l'âge
F. Fajnkuchen (2008)
Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.
Tasanee Braithwaite (2014)
Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion.
Ninel Z. Gregori (2008)
Nonhuman primate models for diabetic ocular neovascularization using AAV2-mediated overexpression of vascular endothelial growth factor.
Corinna Lebherz (2005)
Using the Past to Inform the Future: Anti-VEGF Therapy as a Road Map to Develop Novel Therapies for Diabetic Retinopathy
Paul M. Titchenell (2013)
Inhibition of Tumor Growth and Metastasis by Targeting Tumor-Associated Angiogenesis with Antagonists to the Receptors of Vascular Endothelial Growth Factor
Zhenping Zhu (1999)
Arthur D. Fu (2004)
Intravitreal bevacizumab: an analysis of the evidence
Derrick P Smit (2007)
Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
J. Fernando Arévalo (2008)
Anti-vascular endothelial growth factor therapy for diabetic macular edema
David S Boyer (2013)
Antiangiogenic therapy in neovascular age-related macular degeneration.
Richard C. Lin (2007)
Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California).
Gerard Anthony Lutty (2006)
Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves the antiangiogenic efficacy for advanced stage mouse corneal neovascularization
Zhang Chao-ran (2011)
Vascular plasticity – the role of the angiopoietins in modulating ocular angiogenesis
Antonia Maria Joussen (2001)
Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration
Ilias Zampros (2012)
Emodin-Loaded Magnesium Silicate Hollow Nanocarriers for Anti-Angiogenesis Treatment through Inhibiting VEGF
Hua Ren (2014)
Increased interleukin-6 in aqueous humor of neovascular glaucoma.
K H Chen (1999)
Natural history of choroidal neovascularization induced by vascular endothelial growth factor in the primate
Jing Zhao Cui (2000)
Inhibition of choroidal neovascularization by a peptide inhibitor of the urokinase plasminogen activator and receptor system in a mouse model.
Arup Das (2004)
Vitrectomy with Internal Limiting Membrane Peeling in Acute Central Retinal Vein Occlusion Presenting with Low Vision
Siamak Moradian (2009)
VEGF and the quest for tumour angiogenesis factors
Melvin Greenblatt ()
Inhibition of oxygen-induced retinopathy in RTP801-deficient mice.
Anat Brafman (2004)
Ranibizumab in neovascular age-related macular degeneration
Kenneth T. Eng (2006)
Preliminary Study on Retinal Vascular and Oxygen-related Changes after Long-term Silicone Oil and Foldable Capsular Vitreous Body Tamponade
Wei Yang (2014)
Role of vascular endothelial growth factor in ocular angiogenesis.
Naveed Shams (2006)
See more
Semantic Scholar Logo Some data provided by SemanticScholar